These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3367184)

  • 1. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
    Thiébaud D; Portmann L; Jaeger P; Jacquet AF; Burckhardt P
    Bone; 1986; 7(4):247-53. PubMed ID: 3768203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of neoplastic hypercalcemia using single-infusion diphosphonate].
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    Schweiz Med Wochenschr; 1988 Jan; 118(3):77-81. PubMed ID: 3344411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Bone Miner Res; 1986 Dec; 1(6):555-62. PubMed ID: 3503561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
    Thiébaud D; Jacquet AF; Burckhardt P
    Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
    Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
    Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone.
    Thiebaud D; Jaeger P; Burckhardt P
    J Bone Miner Res; 1990 Mar; 5(3):221-6. PubMed ID: 2333780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate.
    Boudailliez BR; Pautard BJ; Sebert JL; Kremp O; Piussan CX
    Pediatr Nephrol; 1990 Sep; 4(5):510-1. PubMed ID: 2242318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
    Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
    Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ; Dumon JC
    Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
    Wimalawansa SJ
    Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
    Yates AJ; Murray RM; Jerums GJ; Martin TJ
    Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
    Endo K; Katsumata K; Iguchi H; Kubodera N; Teramoto T; Ikeda K; Fujita T; Ogata E
    J Bone Miner Res; 1998 Sep; 13(9):1378-83. PubMed ID: 9738509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
    Mannix KA; Carmichael J; Harris AL; Cantwell BM
    Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
    Davis JR; Heath DA
    Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
    Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
    Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.